sb 202190 has been researched along with Anti-Phospholipid Antibody Syndrome in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jovanović Krivokuća, M | 1 |
| Abu Rabi, T | 1 |
| Stefanoska, I | 1 |
| Vrzić-Petronijević, S | 1 |
| Petronijević, M | 1 |
| Vićovac, L | 1 |
1 other study available for sb 202190 and Anti-Phospholipid Antibody Syndrome
| Article | Year |
|---|---|
Immunoglobulins from sera of APS patients bind HTR-8/SVneo trophoblast cell line and reduce additional mediators of cell invasion.
Topics: Antiphospholipid Syndrome; Cell Line; Cell Movement; Cell Survival; Enzyme Inhibitors; Female; Human | 2017 |